mirtazapin orion 15 mg
orion corporation orion pharma - mirtazapin - smeltetablett - 15 mg
mirtazapin orion 45 mg
orion corporation orion pharma - mirtazapin - smeltetablett - 45 mg
mirtazapin orion 15 mg
orion corporation - espoo - mirtazapin - tablett, filmdrasjert - 15 mg
mirtazapin orion 30 mg
orion corporation - espoo - mirtazapin - tablett, filmdrasjert - 30 mg
mirtazapin orion 45 mg
orion corporation - espoo - mirtazapin - tablett, filmdrasjert - 45 mg
terbinafin bluefish 250 mg
bluefish pharmaceuticals ab - terbinafinhydroklorid - tablett - 250 mg
xenetix 350 mg i/ ml
guerbet - jobitridol - injeksjonsvæske, oppløsning - 350 mg i/ ml
xenetix 250 mg i/ ml
guerbet - jobitridol - injeksjonsvæske, oppløsning - 250 mg i/ ml
xenetix 300 mg i/ ml
guerbet - jobitridol - injeksjonsvæske, oppløsning - 300 mg i/ ml
adcetris
takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastiske midler - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.